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The therapeutic strategies for treating hypertension depends on the patient global cardio-
vascular risk; this risk is not only associated to the severity of increased blood pressure but
also to the presence of other cardiovascular risk factors and of target organs damage such
as left ventricular hypertrophy (LVH). Screening for left ventricular hypertrophy is there-
fore a desirable goal in the management of hypertensive patients, but ECG has a limited
value and echocardiography is not recommended on a routine basis for limited access and
cost-effectiveness reasons [1,2]. Thus, there is a need for surrogate markers.
B-type natriuretic peptides (BNP or NT-proBNP) have been extensively studied in recent
years as a clinical marker of heart overload. BNP is produced mainly by the ventricu-
lar myocardium in response to increased intracavitary pressure and wall stress. Plasma
BNP/NT-proBNP measurement has become an accepted method for diagnosing heart fail-
ure [3]. Moreover, the application of this biochemical marker for guiding the treatment
in chronic heart failure has shown promising results and BNP plasma level also provides
prognostic information in CHF or at discharge after treatment of acute decompensation.
However, the use of plasma BNP for the diagnosis of left ventricular dysfunction or
hypertrophy in the general population or in hypertensives patients has provided more
controversial results [4,5]. In this issue of the journal [6], Mouly-Bertin et al. found a
good accuracy for plasma NT-proBNP to screen for LVH in 93 hypertensive patients, espe-
cially in women with an 88% sensivity and speciﬁcity and positive and negative predictive
values of 76 and 95%, respectively. Beside LV mass index, they also found that 24-h systolic
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mbulatory blood pressure and gender were independent
eterminants of NT-proBNP. Surprisingly, they reported no
tatistical interaction with age, creatine clearance, treat-
ents or diastolic dysfunction. It is noteworthy that the
atients of the study represent a selected population with
very high prevalence of LVH (44%). Moreover, the fact that
bout 25% of the patients (30/123) have been excluded from
he initial analysis subsequently to the echocardiographic
ndings represents an important limitation for the applica-
ion of the results in a hypertensive population. These latter
acts together with the limited number of patients compared
o previous negative studies should have incited the authors
o be more cautious regarding their conclusions.
echanisms of increased plasma BNP in
ypertension
ost studies have shown that LVH was associated with a
igniﬁcant increase in plasma BNP [7]. However, compared
o patients with deﬁnite heart failure, the amplitude of
his elevation is much lower and in the range of elderly
‘normal’’ patients especially. The precise mechanisms of
NP/NT proBNP elevation in hypertension are not fully
nderstood: it can reﬂect both cardiac structural or func-
ional changes such as LVH or LV systolic or diastolic
ysfunction [8] but also their hemodynamic consequences
uch as elevated intracardiac pressures. In hypertension,
levated plasma BNP can be the consequences of increase
ystolic wall stress or increase LV ﬁlling pressure and dias-
olic wall stress [9] and its impact on left atrial stretch
ogether with the increase in LV mass. We can speculate that
or a given ﬁlling pressure the higher the mass, the higher
mount of B type natriuretic peptides can be released. How-
ver, in another sense if we assume that the main mechanism
f secretion is myocyte stretch, a higher wall thickness could
lso contribute to normalize diastolic or systolic wall stress
Laplace law). Therefore, we can speculate that BNP/NT-
roBNP release is probably the result of the balance between
hese different mechanisms.
actors inﬂuencing BNP secretion
ll the studies performed in the general population have
hown that plasma BNP/NTproBNP increase with age and
re higher in female than in male in ‘‘normal’’ subjects.
herefore, when deﬁning threshold for LVH, age and sex
ust surely be taken into account [10].
Moreover, many other cardiac or non cardiac factors
ay inﬂuence B type natriuretic peptide secretion: among
ardiac factors, heart failure, LV systolic or diastolic dys-
unction or more simply increase in LV ﬁlling pressure
ith normal systolic function, and also valvular heart dis-
ase, atrial ﬁbrillation. Several studies have emphasized
he interaction between diastolic dysfunction as a marker
f increased ﬁlling pressure and LVH to explain the increase
f plasma BNP/NT-proBNP in hypertension [8]. On the oppo-
ite, LVH alone with relatively low cardiac ﬁlling pressures
chieved spontaneously or with the use of diuretics or
asodilators can be associated with normal BNP/NT-proBNP
evels, as it is observed in some heart failure patients with LVR. Isnard
ystolic dysfunction [11]. On the opposite, beta-blockers by
ncreasing the diastole duration on a steeper ﬁlling pressure
olume curves could increase the levels of plasma natri-
retic peptides by reaching higher end diastolic pressure
12,13]. Primary or secondary pulmonary hypertension (even
n the absence of left side pathology) can also participate
n an increase of plasma BNP/NT-proBNP. Finally, among non
ardiac factors, renal dysfunction is an important determi-
ant of plasma BNP/NT-proBNP elevation [14], due to both
educed renal natriuretic peptides clearance and expanded
lasma volume, and this factor should certainly be taken
nto consideration in hypertensive patients. In conclusion, it
s wise to think that an increase in plasma BNP/NT-proBNP
s a non speciﬁc marker of ‘‘cardiorenal distress’’, which
sually requires additionnal investigation [4].
ould BNP/NT-proBNP replace
chocardiography in hypertension?
he authors conclude that ECG and NT-proBNP should totally
eplace echocardiography in women and that echocardiog-
aphy should be restricted to men with a negative ECG and a
egative NT-proBNP test. These assumptions need to be dis-
ussed carefully: in fact, we think it is useful to perform an
chocardiography when plasma BNP/NT-proBNP is increased
ecause it is important to ﬁnd out what is wrong with the
eart. Beside LVH, echocardiography could detect abnor-
al systolic function and segmental abnormal wall motion
elated to ischemic cardiac disease. It could also assess the
ype of LVH, eccentric or concentric, which seems related
o different pronostic values. On the opposite, a normal ECG
nd a normal plasma BNP/NTproBNP, in the absence of func-
ional or clinical cardiac signs, are usually associated with
good prognosis, and this probably could avoid the use of
chocardiography even if it can not totally rule out LVH.
In conclusion, although the contribution of Mouly-
ertin et al. is interesting, we actually think that plasma
NP/NT-proBNP are non-speciﬁc markers of cardiac or renal
ysfunction. In the setting of hypertension, it is illusory
o think it should replace echocardiography. Moreover, the
conomic implications of measuring BNP/NT-proBNP in all
ypertensives patients and its impact on healthcare should
eserve careful evaluations before being recommended rou-
inely.
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